Table 1

Baseline demographics and disease state

ETN+MTXMTX
DemographicsVERA (n=63)ERA (n=157)VERA (n=49)ERA (n=148)
Age53.7 (13.6)49.6 (14.9)54.5 (11.9)51.3 (13.3)
Male, n (%)19 (30.2)38 (24.2)17 (34.7)45 (30.4)
Female, n (%)44 (69.8)119 (75.8)32 (65.3)103 (69.6)
Ethnicity, n (%)
 White60 (95.2)132 (84.1)43 (87.8)132 (89.2)
 Black01 (0.6)1 (2.0)1 (0.7)
 Asian2 (3.2)11 (7.0)3 (6.1)6 (4.1)
 Latin American1 (1.6)9 (5.7)2 (4.1)8 (5.4)
 Other03 (1.9)01 (0.7)
Disease state
Disease duration3.6 (0.5)10.7 (5.4)3.5 (0.5)10.3 (5.2)
DAS286.6 (1.0)6.4 (1.0)6.7 (0.9)6.5 (1.0)
SDAI45.0 (14.7)41.6 (15.6)47.7 (15.1)42.7 (14.0)
Swollen joint count*13.7 (7.0)11.6 (6.3)14.1 (6.7)12.2 (6.0)
Tender joint count*15.6 (7.5)13.1 (7.1)15.9 (7.4)13.8 (7.2)
CRP40.4 (46.5)36.9 (36.5)39.6 (32.9)38.4 (33.9)
Erythrocyte sedimentation rate44.2 (25.4)48.4 (23.7)46.9 (22.5)50.8 (24.9)
PtGA7.0 (1.9)6.6 (2.0)6.7 (1.9)6.5 (2.0)
PhGA6.7 (1.6)6.4 (1.6)7.0 (1.4)6.5 (1.5)
mTSS5.5 (12.2)7.0 (13.8)6.7 (15.2)12.4 (23.9)
  • Values are mean (SD) unless otherwise indicated.

  • * Joint counts based on 28 joints. Data not available for calculating SDAI for all subjects.

  • CRP, C reactive protein; DAS, disease activity score; ERA, early rheumatoid arthritis (4 months to 2 years); ETN, etanercept; mTSS, modified total Sharp score; MTX, methotrexate; PhGA, physician global assessment; PtGA, patient global assessment; SDAI, simplified disease activity index; VERA, very early rheumatoid arthritis (≤4 months).